眼睛疾病干细胞治疗的进展:临床试验的进展和未来的前景
Fanfei Liu1, Qiqi Li2, Yang Yang3,4
1Department of Ophthalmology, West China Hospital, Sichuan University, Guoxue xiang, No.37, Chengdu, Sichuan, 610041, China.
Stem cell reviews and reports
|August 19, 2025
概括
干细胞疗法通过修复眼组织,为视力损失提供了希望. 必须克服细胞存活和融合等挑战,才能在治疗眼部疾病方面获得成功的临床应用.
科学领域:
- 眼科医生 眼科 眼科
- 再生医学是一种再生医学.
- 细胞生物学 细胞生物学
背景情况:
- 干细胞疗法显示出治疗视力威胁眼部疾病的潜力.
- 根据分化能力,干细胞被广泛分为多能 (例如ESC,iPSC) 和多能 (例如MSC) 类型.
- 眼睛疾病,如角膜疾病,玻璃眼,视网膜色素炎 (RP) 和与年龄相关的黄斑变性 (AMD) 是干细胞干预的目标.
研究的目的:
- 审查各种眼部疾病的干细胞治疗的临床试验.
- 讨论眼科中干细胞应用的治疗潜力和未来前景.
- 确定阻碍干细胞疗法用于视力恢复的临床转化挑战.
主要方法:
- 对眼部疾病的干细胞疗法现有文献和临床试验数据的审查.
- 不同类型的干细胞 (多能和多能) 的分类和讨论及其相关性.
- 在角膜疾病,青光眼,RP和AMD中的治疗应用的分析.
主要成果:
- 临床前研究表明,恢复视觉功能具有相当大的前景.
- 目前正在进行临床试验,探索干细胞在治疗眼睛病理方面的有效性.
- 确定了一些关键挑战,包括细胞长期存活不足,功能整合不良和瘤转化风险.
结论:
- 干细胞治疗对治疗一系列危及视力的眼睛疾病具有重大前景.
- 克服细胞生存,融合和安全方面的挑战对于临床成功至关重要.
- 进步需要标准化的协议,改进的交付方法和跨学科的合作,以将研究转化为有效的治疗方法.
相关概念视频
iPS Cell Differentiation
2.8K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.8K
Stem Cell Therapy for Tissue Regeneration
4.2K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.2K
Induced Pluripotent Stem Cells
24.4K
Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore...
24.4K
Clinical Applications of Epidermal Stem Cells
2.7K
Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own...
2.7K
Open Angle Glaucoma: Treatment
561
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
561
Angle Closure Glaucoma: Treatment
674
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
674


